XHKG
0474
, Last price
HKD
Name
Aceso Life Science Group Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of construction machinery and spare parts business; provision of repair and maintenance and transportation service business; money lending business; provision of asset management, securities brokerage and other financial service business; property leasing business; and property development business segments. The company leases and sells construction machinery, including crawler cranes, mobile cranes, aerial platforms, and foundation equipment, as well as spare parts; and sells construction materials. It also provides repair and maintenance services for construction machinery; transportation services, such as local container delivery, construction site delivery, and heavy machinery transport; mortgaged and personal loans; and money lending, asset management, commodities, futures, securities brokerage, and other financial services. In addition, the company retails men's and women's apparel; and provides group management, administration, and securities investment services. Further, the company involved in trading of futures and bioscience; and urban development businesses. The company was formerly known as Hao Tian Development Group Limited and changed its name to Aceso Life Science Group Limited in October 2020. Aceso Life Science Group Limited was founded in 1985 and is based in Wan Chai, Hong Kong.
Key people
Shufang Gao
Chief Executive Officer · since 2016
Chief Financial Officer, Executive Director · since 2013
Chan Lai Ping
General Counsel, Secretary · since 2019
Executive Director · since 2012
Executive Director · since 2012
Independent Non-Executive Director · since 2012
Independent Non-Executive Director · since 2012
Independent Non-Executive Director · since 2014
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||